Trade Alert: Executive VP Of Centene Christopher Koster Has Sold Stock

UnitedHealth Group reported $5B in Q2 net income, with a declining medical care ratio. Shares of UnitedHealth, CVS Health, Centene, and Humana have risen significantly. Centene and Humana reported strong earnings, while Humana plans to exit some markets in 2027. Oscar Health entered new markets and saw its stock triple in six months.

Shares of Centene (CNC), UnitedHealth (UNH), CVS (CVS), and Humana (HUM) fell after-hours Tuesday after a report that the Trump administration plans to end a $3.6B federal subsidy for Medicare Part D plans post-2026. The subsidy helps keep premiums low for 25M enrollees. The loss of support could pressure margins and enrollment for insurers offering stand-alone Part D plans, though some beneficiaries may shift to Medicare Advantage plans.

Centene Corp named Chris Neczypor as CFO, replacing Drew Asher, who will step down Dec. 31 and retire end-2027. Neczypor joins from Lincoln Financial Group, where he has been CFO since Feb. 2023. Centene reported a 2025 diluted loss of $13.53/share after a $6.7B goodwill impairment, then Q2 2026 profit of $1.1B on $53.6B revenue, raising 2026 adjusted EPS guidance to >$4.80.

Centene Corp (CNC) shares fell about 3.3% after the company said CFO Drew Asher will step down at year-end and retire by end-2027. Chris Neczypor, formerly CFO at Lincoln Financial, will succeed him effective Jan. 1, 2027, with a transition starting Sept. 2026. Centene reaffirmed 2026 adjusted diluted EPS guidance above $4.80.

Simply Wall St said Centene (CNC) gained attention after reporting Q2 2026 results with higher revenue and a shift to net income, plus raised full-year revenue and earnings guidance on July 28. The article cites a 7-day return of 4.41% and YTD return of 59.33%, and contrasts valuation views using a $63.78 fair value vs a DCF estimate of $188.62.

Centene (CNC) shares rose 5.2% as investors digested late-July results showing improved profitability and cost control. The company reported Q2 2026 adjusted diluted EPS of $2.51 on $44.4B revenue, with the health benefits ratio improving to 89.6%. Centene raised its 2026 adjusted EPS outlook to over $4.80 from over $3.40, citing better Medicaid and Marketplace margins.